Sign In
Buy HCWB
$3.20
+0.0500 (+1.59%)
At Close: Jul 31, 2026
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
08:10am, Monday, 23'rd Dec 2024
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWS
MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering an
Why Is Penny Stock HCW Biologics Surging On Monday?
10:15am, Monday, 18'th Nov 2024
HCW Biologics Inc HCWB stock is trading higher during Monday premarket with a strong session volume of 10.03 million versus an average volume of 48.02K, as per data from Benzinga Pro.
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
07:00am, Monday, 18'th Nov 2024
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million an
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
04:40pm, Thursday, 14'th Nov 2024
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
04:30pm, Friday, 23'rd Aug 2024
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
04:35pm, Wednesday, 14'th Aug 2024
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
04:39pm, Wednesday, 15'th May 2024
MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and deve
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
04:10pm, Monday, 01'st Apr 2024
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
07:00am, Tuesday, 14'th Nov 2023
MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable
MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
07:30am, Wednesday, 06'th Sep 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update f
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
07:00am, Friday, 11'th Aug 2023
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
HCW Biologics Enters CRADA with National Cancer Institute
12:55pm, Thursday, 08'th Dec 2022 GlobeNewswire Inc.
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Adv
